154 related articles for article (PubMed ID: 38184732)
1. EPYC functions as a novel prognostic biomarker for pancreatic cancer.
Yang Z; Li H; Hao J; Mei H; Qiu M; Wang H; Gao M
Sci Rep; 2024 Jan; 14(1):719. PubMed ID: 38184732
[TBL] [Abstract][Full Text] [Related]
2. Epiphycan Predicts Poor Outcomes and Promotes Metastasis in Ovarian Cancer.
Deng L; Wang D; Chen S; Hu W; Zhang R
Front Oncol; 2021; 11():653782. PubMed ID: 34888227
[TBL] [Abstract][Full Text] [Related]
3. TEAD4 functions as a prognostic biomarker and triggers EMT via PI3K/AKT pathway in bladder cancer.
Chi M; Liu J; Mei C; Shi Y; Liu N; Jiang X; Liu C; Xue N; Hong H; Xie J; Sun X; Yin B; Meng X; Wang B
J Exp Clin Cancer Res; 2022 May; 41(1):175. PubMed ID: 35581606
[TBL] [Abstract][Full Text] [Related]
4. Construction of a novel model based on cell-in-cell-related genes and validation of KRT7 as a biomarker for predicting survival and immune microenvironment in pancreatic cancer.
Song J; Ruze R; Chen Y; Xu R; Yin X; Wang C; Xu Q; Zhao Y
BMC Cancer; 2022 Aug; 22(1):894. PubMed ID: 35974300
[TBL] [Abstract][Full Text] [Related]
5. Long noncoding RNA ABHD11-AS1 predicts the prognosis of pancreatic cancer patients and serves as a promoter by activating the PI3K-AKT pathway.
Qiao X; Lv SX; Qiao Y; Li QP; Ye B; Wang CC; Miao L
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8630-8639. PubMed ID: 30575903
[TBL] [Abstract][Full Text] [Related]
6. CYP26A1 Is a Novel Cancer Biomarker of Pancreatic Carcinoma: Evidence from Integration Analysis and
Yu Y; Wang Y; Zou Y; Yu Y
Dis Markers; 2022; 2022():5286820. PubMed ID: 35707714
[TBL] [Abstract][Full Text] [Related]
7. microRNA-382 suppresses the progression of pancreatic cancer through the PI3K/Akt signaling pathway by inhibition of Anxa3.
Wan X; Guo D; Zhu Q; Qu R
Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G309-G322. PubMed ID: 32463333
[TBL] [Abstract][Full Text] [Related]
8. EG-VEGF silencing inhibits cell proliferation and promotes cell apoptosis in pancreatic carcinoma via PI3K/AKT/mTOR signaling pathway.
Yan X; Hui Y; Hua Y; Huang L; Wang L; Peng F; Tang C; Liu D; Song J; Wang F
Biomed Pharmacother; 2019 Jan; 109():762-769. PubMed ID: 30551529
[TBL] [Abstract][Full Text] [Related]
9. Identification of candidate diagnostic and prognostic biomarkers for pancreatic carcinoma.
Cheng Y; Wang K; Geng L; Sun J; Xu W; Liu D; Gong S; Zhu Y
EBioMedicine; 2019 Feb; 40():382-393. PubMed ID: 30639415
[TBL] [Abstract][Full Text] [Related]
10. Identification of key microRNAs and their targets in exosomes of pancreatic cancer using bioinformatics analysis.
Zhao X; Ren Y; Cui N; Wang X; Cui Y
Medicine (Baltimore); 2018 Sep; 97(39):e12632. PubMed ID: 30278585
[TBL] [Abstract][Full Text] [Related]
11. COL17A1 facilitates tumor growth and predicts poor prognosis in pancreatic cancer.
Yang J; Li Y; Sun Z; Fan Z; Shi M; Liu S; Meng Y; Zhou B; Jiang Y; Zhan H
Biochem Biophys Res Commun; 2022 Dec; 632():1-9. PubMed ID: 36191371
[TBL] [Abstract][Full Text] [Related]
12. Gene signature for prognosis in comparison of pancreatic cancer patients with diabetes and non-diabetes.
Yang M; Song B; Liu J; Bing Z; Wang Y; Yu L
PeerJ; 2020; 8():e10297. PubMed ID: 33240632
[TBL] [Abstract][Full Text] [Related]
13. Necroptosis-Related Prognostic Model for Pancreatic Carcinoma Reveals Its Invasion and Metastasis Potential through Hybrid EMT and Immune Escape.
Liu H; Li Z; Zhang L; Zhang M; Liu S; Wang J; Yang C; Peng Q; Du C; Jiang N
Biomedicines; 2023 Jun; 11(6):. PubMed ID: 37371833
[TBL] [Abstract][Full Text] [Related]
14. Screening and Validation of Independent Predictors of Poor Survival in Pancreatic Cancer.
Liu S; Cai Y; Changyong E; Sheng J; Zhang X
Pathol Oncol Res; 2021; 27():1609868. PubMed ID: 34321959
[TBL] [Abstract][Full Text] [Related]
15. NUF2 promotes tumorigenesis by interacting with HNRNPA2B1 via PI3K/AKT/mTOR pathway in ovarian cancer.
Ren M; Zhao H; Gao Y; Chen Q; Zhao X; Yue W
J Ovarian Res; 2023 Jan; 16(1):17. PubMed ID: 36670423
[TBL] [Abstract][Full Text] [Related]
16. Unveiling the role of PYGB in pancreatic cancer: a novel diagnostic biomarker and gene therapy target.
Ren LK; Lu RS; Fei XB; Chen SJ; Liu P; Zhu CH; Wang X; Pan YZ
J Cancer Res Clin Oncol; 2024 Mar; 150(3):127. PubMed ID: 38483604
[TBL] [Abstract][Full Text] [Related]
17.
Deng Y; Ma H; Hao J; Xie Q; Zhao R
Biomed Res Int; 2020; 2020():8604340. PubMed ID: 32420375
[TBL] [Abstract][Full Text] [Related]
18. DUOX2 As a Potential Prognostic Marker which Promotes Cell Motility and Proliferation in Pancreatic Cancer.
Cao M; Zhang PB; Wu PF; Chen Q; Ge WL; Shi GD; Yin J; Cai BB; Cao SJ; Miao Y; Jiang KR
Biomed Res Int; 2021; 2021():6530298. PubMed ID: 33748270
[TBL] [Abstract][Full Text] [Related]
19. RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway.
Hua H; Xie H; Zheng J; Lei L; Deng Z; Yu C
Oxid Med Cell Longev; 2023; 2023():1728463. PubMed ID: 36644576
[TBL] [Abstract][Full Text] [Related]
20. System analysis based on the pyroptosis-related genes identifies GSDMC as a novel therapy target for pancreatic adenocarcinoma.
Yan C; Niu Y; Li F; Zhao W; Ma L
J Transl Med; 2022 Oct; 20(1):455. PubMed ID: 36199146
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
